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Abstract 
Background: Socio-demographic and behavioural characteristics are associated with delayed diagnosis 
and disease progression in HCV-infected persons. However, many analyses focused on single variables 
rather than groups defined by several variables. 
Methods: We used latent class analysis to study all 4,488 persons enrolled in the Swiss Hepatitis C Cohort 
Study. Groups were identified using pre-defined variables at enrolment. The number of groups was 
selected using the Bayesian Information Criterion. Mortality, loss to follow-up, cirrhosis, treatment status 
and response to antivirals were analysed using Laplace and logistic regressions. 
Results: We identified five groups and named them according to their characteristics: persons who inject 
drugs, male drinkers, Swiss employees, foreign employees and retirees. Two groups did not conform to 
common assumptions about persons with chronic hepatitis C and were already in an advanced stage of 
the disease at enrolment: “male drinkers” and “retirees” had a high proportion of cirrhosis at enrolment 
(15% and 16% vs <10.3%), and the shortest time to death (adjusted median time 8.7 years and 8.8 years 
vs >9.0). “Male drinkers” also had high substance use, but they were well educated and were likely to be 
employed.  
Conclusions: This analysis may help identifying high risk groups which may benefit from targeted 
interventions. 
 
 
 
Key words: alcohol, hepatitis C, latent class analysis, persons who inject drugs, socio-behaviour, 
Switzerland 
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Introduction 
Hepatitis C virus (HCV) infection is one of the major causes of chronic hepatitis, cirrhosis and hepatocellular 
carcinoma. HCV-associated complications are increasingly prevalent in Switzerland and other countries 
[1–5]. New options to treat HCV with direct-acting antivirals (DAA) can reach sustained virologic response 
rates (SVR) between 85% and 100% [5–7]. These new treatments will decrease the long-term risk of liver 
disease complications, but more than 50% of HCV cases are still undiagnosed in Switzerland [1,2,8] and 
elsewhere [1,7,9]. To reap the full benefit of the new HCV therapies, testing coverage must increase, and 
testing must be linked to care. 
Socio-demographic and behavioural characteristics are associated with delayed diagnosis or treatment, 
[10–12] as well as adherence to treatment [10,11]. Among other factors, studies have associated age [13], 
gender [14], and alcohol consumption [15] with access to therapy, but they have usually focused on single 
variables. The combined effect of several characteristics could be evaluated with a person-centred 
approach, which would begin by grouping persons with similar characteristics and then determining the 
associations between these groups and specific outcomes. 
Clinicians must make many decisions when they interact with persons, decide on appropriate treatments, 
and adapt treatments to persons. The practice of diagnostic reasoning is central to daily patient 
management, especially in personalized health care settings [16]. For example, clinicians may decide to 
test a patient for HCV if they suspect intravenous drug use. Similarly, when clinicians decide whether to 
treat a patient or not, they will consider both biomedical aspects and the context in which treatment is 
prescribed, including a patient’s tolerance for medication, lifestyle and anticipated adherence to therapy 
[16]. Clinicians often categorize persons, based on both clinical observation and their perception of the 
patient’s personal characteristics [17]. Diagnostic reasoning is a complex process, and it can be supported 
by latent class analysis (LCA) [18], a multivariate statistical analysis technique that can identify distinct 
subgroups (latent classes) that cannot be observed directly, but are inferred from available data [18]. In 
LCA, heterogeneity within the classes is low, and the variables that define classes are independent. We 
used LCA in the Swiss Hepatitis C Cohort Study (SCCS) to: (1) define different socio-demographic and 
behavioural groups; (2) describe the characteristics of these groups; (3) determine if belonging to these 
groups is associated with access to care and clinically relevant outcomes (for example, high risk of loss-to-
follow-up, developing cirrhosis, or poor treatment response). 
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Materials and methods 
Swiss Hepatitis C Cohort Study (SCCS) 
The SCCS, established in 2000, includes persons aged ≥18 years with positive anti-HCV antibodies [19]. 
Participants are enrolled at eight centres, including five university teaching hospitals (Basel, Bern, Geneva, 
Lausanne and Zurich), two regional hospitals (Neuchatel and St. Gallen) and a regional hepatology centre 
(Lugano) [19]. Data are collected by standardized questionnaires, which are completed during clinical visits 
at enrolment and annual follow-up. Data comprise socio-demographic and behavioural information, 
including gender, date of birth, nationality, the occupational situation, education, risk factors for HCV 
infection, and drug and alcohol consumption. There is also data from clinical evaluations: anthropometric 
measures and assessments of liver cirrhosis; laboratory tests, including assays for liver function, HCV viral 
load and genotype, serological markers of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) 
infections; and Fibroscan® and/or liver histology results. Data quality is checked periodically by the Clinical 
Trial Unit at the University Hospital Basel. Ethical approval for data collection was obtained from the ethics 
committees of the eight participating centres. All subjects gave informed consent. 
 
Eligibility criteria and definitions 
The study included all patients enrolled as of December 31st, 2014. We categorized the following variables 
for the LCA: age (≤40, 41-59, ≥60 years), nationality (Swiss, foreign), and occupational status (working or 
studying, unemployed, retired or social assistance). Additionally, we defined participants as persons who 
inject drugs (PWID) if previous or ongoing injecting drug use was mentioned in the questionnaire (in a 
sensitivity analysis we considered three groups: no, current, former drug use); and as no or light drinkers 
of alcohol (≤20 g alcohol/day), moderate to heavy drinkers (>20 g alcohol/day), or former moderate to 
heavy drinkers (used to drink >20 g alcohol/day before, but currently stopped). Education (low, medium, 
high) was classified according to the definitions provided by the Swiss Conference of Cantonal Ministers 
of Education [20]. We grouped HCV genotypes into categories 1 to 4 (genotypes 5 and 6 were set to missing 
since only 11 persons had these genotypes). Since in most cases the date of HCV infection was unknown 
or uncertain, we used the date of the first positive anti-HCV test as a proxy and classified the persons into 
four groups (≤1, 2-5, 6-10, >10 years from date of first positive test to date of enrolment). 
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Latent Class Analysis 
We used LCA to define groups of persons whose socio-demographic and behavioural characteristics were 
similar at enrolment into the cohort. We chose and categorized variables before we began the analysis. 
The following variables defined the groups: gender, age, education, occupational situation, nationality, 
drug use, and alcohol consumption. We conducted the analysis in steps, beginning with one class and then 
increasing the number of classes by one. We used the Bayesian Information Criterion (BIC) to define the 
optimal number of classes [21]. Based on their socio-demographic and behavioural characteristics, persons 
were assigned to groups they were most likely to belong to. We used Mplus software (Muthen & Muthen, 
Los Angeles, CA, USA, 2009) for the LCA. 
 
Outcomes 
We considered five outcomes: antiviral treatment status, response to antivirals, cirrhosis, loss to follow-
up, and mortality. Persons were considered to have been treated if they had ever received any medication 
against HCV. Virologic response to therapy was classified as sustained virologic response (SVR) or failure, 
and was based on viral load assessment after the end of the most recent treatment, regardless of the type 
of treatment. Failure was defined as any detectable HCV RNA after treatment end. Persons who had 
undetectable HCV RNA 12 weeks after the end of treatment were deemed to have achieved SVR. We 
excluded from the analysis persons whose HCV RNA was measured only before or during treatment. 
Persons were considered lost to follow-up (LTFU) if their last visit was more than 2 years before the closing 
date of the analysis (December 31st 2014), unless they had died. The analysis of LTFU only included persons 
registered ≥2 years before the closing date. 
 
Statistical Analysis 
We performed Laplace regressions [22] for time to event analyses (cirrhosis, loss to follow-up and 
mortality). We measured time from enrolment into the cohort until the date of the event, last follow-up 
visit, or death (whichever occurred first). We censored our analysis after 5 years of follow-up because few 
persons were followed for more than 5 years. We performed logistic regression to determine treatment 
status and virologic response, and adjusted our analyses for the following variables: time since diagnosis, 
HCV genotype, co-infection with HIV, chronic co-infection with HBV, and study site. Models for loss to 
follow-up, mortality, treatment status and virologic response were also adjusted for cirrhosis at enrolment 
(Figure 1). Persons whose HIV status was missing were considered HIV-negative. We used Cox models for 
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sensitivity analysis, and used multiple imputation for all missing values of explanatory variables. We 
imputed missing values with chained equations for 20 imputed datasets. We used the following variables 
in imputation equations: HIV, chronic HBV, HCV genotype, time since diagnosis, cirrhosis at enrolment, 
LCA groups, study site, the binary indicator for the event, and the Nelson-Aalen estimator of the 
cumulative hazard to the survival time [23]. We also performed a complete case analysis, excluding 
persons with any missing covariable. Results are presented as time to event (years) or odds ratio (OR). We 
used Stata software (version 13.1, Stata Corporation, College Station, Texas, USA, 2013) for analyses.  
Giudici, Bertisch     7 
 
Results 
A total of 4,488 SCCS persons were included in the study. The majority were males (n=2,830; 63.1%), Swiss 
(3,292; 73.4%), and over half were PWID (2,530; 56.5%), of which 493 (19.5%) were former drug users 
(Table 1, Table 4 in supplementary material). Median age at enrolment was 43 years (IQR 36-51 years). 
Almost half of the persons had genotype 1 (2,166; 48.3%), more than a quarter had genotype 3 (1,183; 
26.4%), genotype 4 was the next most common (422; 9.4%), followed by genotype 2 (354; 7.9%). The 
percentage of missing values was generally low (maximum 1.5%), except for HIV co-infection (21%), HBV 
co-infection (9%) and HCV genotype (8%). 
 
Socio-behavioural groups identified by latent class analysis 
Based on the LCA, we chose a five-class model because it had a smaller BIC value than models with fewer 
or more classes. The BIC is one of the most common criteria for model selection among a finite set of 
models; the model with the lowest BIC is preferred [21]. Figure 2 shows how groups with corresponding 
BIC values developed as the number of classes increased. The group “PWID” was the first group we 
identified (G1 in model 2). The second group (G2 in model 2) later split into “Swiss employees” and 
“retirees”. For 2,530 (56.4%) persons, the probability of belonging to the group they were assigned to was 
≥0.80, for 845 (18.8%) persons, this probability was <0.60, so group allocation was less certain. The “Swiss 
employees” included a few unemployed persons (35/1129; 3.1%), and “PWID” contained a few persons 
with no history of injecting drug use (non-PWID; 16/1642; 1.0%). The two groups, “foreign employees” 
and “retirees”, incorporated some PWID (38/497; 7.6%) and moderate to heavy drinkers (56/599, 9.3%). 
Median membership probability ranged from 0.61 (IQR 0.57-0.64) in ”male drinkers” to 0.99 (IQR 0.94-
1.00) in “retirees”. Box 1 summarizes the groups we found through LCA. Table 1 shows the characteristics 
of the groups. Results were similar in the sensitivity analysis when former and current PWID were split into 
two categories (Table 4, supplementary material).  
 
Outcomes 
All 4,488 persons were included in our analysis of treatment status and over half (2,436; 54.3%) received 
treatment. The percentage of treatment uptake was lower in “PWID” (732; 44.6%), higher in “Swiss 
employees” (641; 56.8%) and around 60% for the other groups: “male drinkers” (381; 61.3%), “foreign 
employees” (316; 63.6%) and “retirees” (366; 61.1%). The odds ratio to be treated was significantly lower 
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for “PWID” (adjusted OR 0.54, 95% CI 0.42-0.69) and for “retirees” (adjusted OR 0.69, 95% CI 0.51-0.92) 
compared to “foreign employees” (Table 2). A total of 1,967 (43.8%) persons were included in our analysis 
of virologic response; of these, almost half (957; 48.6%) had achieved SVR. The “retirees” had the lowest 
percentage of SVR (103; 34.3%), while SVR was highest in “PWID” (326; 55.8%) and “foreign employees” 
(140; 55.8%). Almost half of “Swiss employees” (260; 48.7%) achieved SVR and this percentage was slightly 
lower in “male drinkers” (128; 42.9%). The odds ratio of reaching SVR was lower in “retirees” than in 
“foreign employees” (adjusted OR = 0.48, 95% CI 0.32-0.72; Table 2), but no difference was apparent for 
other groups. A total of 237 (5.3%) persons died, 1,364 (30.4%) were lost to follow-up, and 897 (20.0%) 
developed cirrhosis. Table 2 shows the corresponding estimated median time from enrolment to these 
events calculated with Laplace regression. The adjusted median time to death was similar across groups, 
ranging from 8.7 years after enrolment in “male drinkers” to 10.1 years in “Swiss employees”. The overall 
median adjusted time to loss to follow-up was 5.4 years after enrolment, but was significantly longer in 
“Swiss employees” (6.0 years). In other groups, median adjusted time ranged between 4.8 ("PWID") and 
5.9 years (“retirees”). “Swiss employees” took the longest time to develop cirrhosis after enrolment (9.5 
years), and it developed soonest in “retirees” (5.0 years) and “male drinkers” (6.1 years). Results were 
similar when we conducted sensitivity analyses, trying different approaches to handle missing data (Table 
3).  
  
Giudici, Bertisch     9 
 
Discussion 
Main findings 
LCA revealed five distinct socio-behavioural groups of HCV-infected persons enrolled in the SCCS. The 
groups had different characteristics at enrolment, and different outcomes for treatment status, virologic 
response, development of cirrhosis, loss to follow-up, and death. 
 
Groups of persons with (a history of) injecting drug use 
Since PWID are the largest HCV risk group in Switzerland, it is no surprise they were the biggest LCA group 
(37% of all persons). They had characteristics that are frequently reported for PWID, including young age 
[11,24,25], a lower percentage of women (32%) [14] than in the overall population, high unemployment 
(23%) [24,26], and previous or ongoing moderate to heavy alcohol consumption (61%) [10,24–26]. We 
identified two more groups with a high rate of PWID: “male drinkers” and "Swiss employees", with 69% 
and 39% of persons with a history of injecting drug use respectively. These two groups include more 
“integrated” PWID who are well educated (96% and 92% persons with medium to high level of education) 
and likely to be employed (63% and 96%).  
 
Groups of persons without (a history of) injecting drug use 
People who did not acquire HCV via intravenous drug use were frequently documented among “foreign 
employees” and “retirees”. Most HCV infections in resource-limited countries are caused by unsafe 
medical procedures [27,28]. In the European birth countries of many Swiss immigrants, healthcare-
associated infections were also common at some points in time; e.g. in Italy and Spain, healthcare-
associated infections were frequent from 1950 to 1970 [4,29–32].  
 
Treatment outcomes and access to therapy  
Group membership was associated with relevant outcomes like cirrhosis, loss to follow-up and mortality. 
Among all groups, “male drinkers”, despite their young age (median age: 48 years old), had the shortest 
time to death and second shortest time to cirrhosis after being enrolled. We suppose that alcohol is the 
decisive factor, with 100% ongoing or former moderate to high alcohol consumption. Alcohol-associated 
liver disease may also have caused their poor treatment outcome: despite the second-highest treatment 
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rate, “male drinkers” had the second-worst treatment response. The “PWID” group had the shortest time 
to loss to follow-up after enrolment. This was expected, as PWID are more prone to miss appointments 
[33]. “PWID” was also the youngest group, so its members may be more mobile. Despite their youth, 
mortality in this group was relatively high and time to death was close to the overall median time to death 
across all groups. We assume that death was mostly caused by drug-related illness or accidents. HCV-
associated disease progresses more slowly in young people, so treatment may have been postponed. 
Alternatively treatment may have been delayed because interferon-α (IFN-α) has major psychiatric side 
effects and PWID often have psychiatric comorbidities [10,24]. But when they were treated, these persons 
had the second-highest virologic response. This finding is in line with publications that showed comparable 
treatment success in PWID and in people who do not inject drugs [10,11,24,26]. 
“Retirees” developed cirrhosis in the shortest period of time and had the second shortest time to death. 
A high proportion of “retirees” were in an advanced stage of liver disease at enrolment. These persons 
were probably diagnosed late, since awareness about HCV in older people is low in the general population 
and among clinicians. Older age is also a risk factor for faster progression of liver disease and cirrhosis [13]. 
Our study confirmed that old people are persons with little loss to follow-up, but despite this and the 
higher rate of cirrhosis, treatment uptake among “retirees” was low. Clinicians may have been reluctant 
to treat old persons with IFN-α and ribavirin (RBV) because in old persons treatment-related anaemia is 
more frequent and its consequences more severe [13].  
“Foreign employees” and “Swiss employees” presented quite similar results. Both groups had the longest 
time to death and the longest time to cirrhosis, probably reflecting a combined effect of their young age 
and low alcohol consumption. Treatment status and virologic response were not significantly different, 
perhaps because both have good access to healthcare. 
Access to antiviral therapy was similar across groups, which is not surprising in view of the limited choice 
of medicaments during many years. The decision when and how to treat was based on the estimated 
treatment need, anticipated side effects and cure rates of the drugs available at the time the persons were 
treated. DAAs were rarely used (2.4% overall) probably because reimbursement for the first DAA 
substance started in August 2014 in Switzerland. DAA use was more frequent in “retirees” and “male 
drinkers”. These groups had the highest proportion of persons in Metavir stage F3 or F4 at enrolment into 
the cohort (25% and 24%) and by far the highest rate of advancement to cirrhosis. Thus, there was an 
urgent treatment need, and they were entitled to obtain DAA which, up to the date of censoring, in 
Switzerland had been restricted to persons in Metavir stage F3 and F4. 
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Strengths and Weaknesses 
The SCCS includes only a limited proportion of all HCV-infected persons in Switzerland, the total number 
of infections being estimated at 82,700 in 2013 [3]. However, patient characteristics are comparable to 
official national notification data [19], so our results should be generalizable to HCV-infected persons in 
Switzerland and possibly other countries with similar socio-economic characteristics. 
The information collected at enrolment into the SCCS covers a wide range of socio-behavioural variables. 
The decision which variables to include in the LCA was subjective, but was done a priori. We found median 
probability of belonging to the “male drinkers” group was rather low (p=0.61) and there was some chance 
that persons assigned to this group could potentially belong to the “Swiss employees” or “PWID” groups. 
But membership probabilities for the other groups were high, and the model was able to create 
heterogeneous groups. LCA is based on a likelihood-based model and uses objective criteria to determine 
the best fit i.e. the optimal number of classes. LCA can also easily deal with categorical data and missing 
values. 
In general, only a small proportion of values in the socio-behavioural variables was missing (<1.5% for all 
variables). The proportion of missing values was higher for some covariables we included in the 
multivariable analyses (HIV co-infection 21%, chronic HBV co-infection 9% and HCV genotype 8%). 
Probably persons with missing HIV values were more likely to be HIV-negative, and we therefore 
considered them to be negative. However, in the sensitivity analysis where we used multiple imputation, 
and in the complete case analysis (where persons with missing values were excluded), results were similar.  
We used the date of diagnosis rather than the date of infection, as the time of infection was often 
unknown. PWID were probably diagnosed and enrolled earlier into the cohort than persons of other risk 
groups. It is therefore not surprising that non-PWID were in a more advanced stage of the disease at 
enrolment. In the main analyses we combined former and current PWID in one group since both groups 
are equally at risk of HCV infection. However, results were similar in the sensitivity analysis where people 
were categorized into “no”, “former” and “current” PWID. 
Defining virologic response was difficult, since HCV RNA values were often not recorded at the 
recommended time points, or the date the patient stopped therapy was missing. Nevertheless, we were 
able to clearly classify the virologic response of the majority of persons (96%) we included in the analysis. 
We were also limited by self-reporting of data on drug use and alcohol consumption, which may have been 
biased by social desirability and recall. About 5% of persons were reported to have died, but deaths were 
probably underreported and persons lost to follow-up may have died. 
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Implications of findings and future research 
We used a person-centred approach to identify groups of persons with similar characteristics. Our 
approach reflects more closely the process of clinical decision-making, where clinicians use patient 
characteristics to decide who should be tested for HCV and how to optimize care in diagnosed persons. 
We identified two groups that do not conform to common assumptions about persons with chronic 
hepatitis C, while presenting at an advanced stage of the disease and with bad treatment outcomes. The 
“male drinkers” have high substance use, but are also well educated and likely to be employed. If, in the 
population, persons with these characteristics do not volunteer information about drug use, the clinician 
may not ask questions concerning injecting drug use (and a possibly associated HCV infection). There is 
thus a risk of under-diagnosis especially if these persons are not currently using drugs. Similarly, retirees, 
frequently infected outside intravenous drug use, may also be underdiagnosed. The proportion of persons 
with advanced liver disease is high at enrolment into the cohort in both of these groups. 
 
Conclusions 
Using LCA, we were able to identify groups of persons with delayed access to care and poor treatment 
outcomes. LCA may therefore be a powerful tool for identifying high-risk subgroups that may be missed 
with a single-variable approach. This information may be useful to design targeted interventions. 
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Table 1: Participant characteristics in the socio-behavioural groups identified by the latent class analysis 
 
 Swiss 
employees 
PWID Male 
drinkers 
Foreign 
employees 
Retirees Total 
No. of participants (%) 1,129 (25.2) 1,642 (36.6) 621 (13.8) 497 (11.1) 599 (13.3) 4,488 (100.0) 
No. of women 618 (54.7) 526 (32.0) 6 (1.0) 203 (40.8) 305 (50.9) 1,658 (36.9) 
Median (interquartile range) 
   age, years 
44 (38-50) 37 (32-42) 48 (44-52) 41 (35-49) 64 (60-68) 43 (36-51) 
Swiss nationality 1,113 (98.6) 1,252 (76.2) 522 (84.1) 0 (0.0) 405 (67.6) 3,292 (73.4) 
Educationa       
   lower 77 (6.8) 603 (36.7) 14 (2.2) 138 (27.8) 134 (22.4) 966 (21.8) 
   medium 689 (61.0) 1,001 (61.0) 450 (72.5) 200 (40.2) 334 (55.8) 2,674 (60.5) 
   higher 344 (30.5) 20 (1.2) 148 (23.8) 150 (30.2) 119 (19.9) 781 (17.7) 
Occupational situation       
   worker/student 1,078 (95.5) 687 (41.8) 394 (63.4) 447 (89.9) 131 (21.9) 2,737 (61.3) 
   retired/social assistance 10 (0.9) 563 (34.3) 192 (30.9) 9 (1.8) 462 (77.1) 1,236 (27.7) 
   unemployed 35 (3.1) 385 (23.4) 33 (5.3) 37 (7.4) 3 (0.5) 493 (11.0) 
Alcohol consumptionb       
   no or light drinker 979 (86.7) 637 (38.8) 0 (0.0) 375 (75.4) 442 (73.8) 2,433 (54.2) 
   moderate-heavy drinker 39 (3.4) 331 (20.2) 211 (34.0) 26 (5.2) 56 (9.3) 663 (14.8) 
   former moderate-heavy drinker 111 (9.8) 674 (41.0) 410 (66.0) 96 (19.3) 101 (16.9) 1,392 (31.0) 
Drug use (former or ongoing)c 437 (38.7) 1,625 (99.0) 429 (69.1) 38 (7.6) 1 (0.2) 2,530 (56.5) 
Recorded HCV risk factorsd 911 (80.7) 1,353 (82.4) 531 (85.5) 373 (75.1) 456 (76.1) 3,624 (80.7) 
Antiviral therapy       
   Peginterferon/Ribavirin 596 (52.8) 693 (42.2) 340 (54.7) 287 (57.7) 324 (54.1) 2,240 (49.9) 
   Boceprevir/Telaprevir 14 (1.2) 7 (0.4) 9 (1.5) 10 (2.0) 6 (1.0) 46 (1.0) 
   DAA 21 (1.9) 23 (1.4) 21 (3.4) 14 (2.8) 27 (4.5) 106 (2.4) 
Fibrosis (stage)       
   F0 89 (7.9) 88 (5.4) 26 (4.2) 31 (6.2) 31 (5.2) 265 (5.9) 
   F1 209 (18.5) 245 (14.9) 76 (12.2) 112 (22.5) 62 (10.3) 704 (15.7) 
   F2 183 (16.2) 235 (14.3) 87 (14.0) 61 (12.3) 91 (15.2) 657 (14.6) 
   F3 69 (6.1) 73 (4.4) 57 (9.2) 44 (8.8) 55 (9.2) 298 (6.6) 
   F4 85 (7.5) 108 (6.6) 93 (15.0) 51 (10.3) 96 (16.0) 433 (9.6) 
PWID: persons who inject drugs 
a Education: defined according to the Swiss Conference of Cantonal Ministers of Education. 
b Alcohol consumption: no or light drinker (≤20 g alcohol/day), moderate-heavy drinker (>20 g alcohol/day) and former 
moderate-heavy drinker (used to drink >20 g alcohol/day before, but currently stopped). 
c Drug use: ever injected drugs. 
d Recorded HCV risk factors: medical procedures, intranasal drugs, transfusion, high risk sexual behaviour, partner HCV positive, 
accidental needle prick, profession in contact with blood, HCV positive person in household, piercing and/or tattoo. 
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Table 2: Treatment status, response to antivirals and time (in years) to cirrhosis/loss to follow-up/death by LCA 
groups 
 
 Treatment status Response to antivirals 
 N = 4,488  N = 3,768  N = 1,967  N = 1,785  
 Unadjusted OR  Adjusteda OR  Unadjusted OR  Adjusteda OR  
 (95% CI) p (95% CI) p (95% CI) p (95% CI) p 
Socio-behavioural 
groups 
        
Foreign employees 1  1  1  1  
Swiss employees 0.75 (0.61;0.94) 0.010 0.85 (0.66;1.09) 0.191 0.75 (0.56;1.02) 0.064 0.78 (0.55;1.10) 0.152 
PWID 0.46 (0.37;0.57) <0.001 0.54 (0.42;0.69) <0.001 1.00 (0.74;1.35) 0.990 0.93 (0.66;1.31) 0.675 
Male drinkers 0.91 (0.71;1.16) 0.445 0.93 (0.69;1.24) 0.602 0.60 (0.43;0.84) 0.003 0.70 (0.47;1.03) 0.071 
Retirees 0.90 (0.70;1.15) 0.399 0.69 (0.51;0.92) 0.012 0.41 (0.29;0.59) <0.001 0.48 (0.32;0.72) <0.001 
       
 Time to cirrhosis Time to loss to follow-up Time to death 
 Unadjusted  
msp 
Adjustedb  
msp 
Unadjusted  
msp 
Adjustedc  
msp 
Unadjusted  
msp 
Adjustedc  
msp 
 N = 4,458 N = 3,769 N = 4,054 N = 3,491 N = 4,482 N = 3,763 
Socio-behavioural 
groups 
      
Foreign employees 7.8 8.4 5.8 5.3 9.6 9.4 
Swiss employees 0.5 (-0.4;1.3) 1.1 (0.2;2.1) 0.5 (0.0;0.9) 0.7 (0.2;1.2) 1.1 (-0.1;2.4) 0.7 (-0.5;1.8) 
PWID -0.3 (-1.1;0.5) 0.2 (-0.7;1.1) -0.5 (-0.9;-0.1) -0.5 (-1.0;0.1) -0.3 (-1.3;0.8) -0.4 (-1.5;0.6) 
Male drinkers -2.4 (-3.2;-1.6) -2.3 (-3.4;-1.2) 0.6 (0.1;1.1) 0.4 (-0.2;1.0) -1.7 (-2.8;-0.6) -0.7 (-1.8;0.3) 
Retirees -2.6 (-3.4;-1.7) -3.4 (-4.6;-2.1) 0.9 (0.3;1.4) 0.6 (0.0;1.3) -1.5 (-2.6;-0.4) -0.6 (-1.6;0.5) 
PWID: persons who inject drugs (former or current) 
Treatment status and response to antivirals using logistic regression 
      OR: odds ratio with 95% confidence interval (CI) 
      a Adjusted for: HCV genotype, cirrhosis at enrolment, time since diagnosis, chronic HBV infection, HIV infection, study site 
Time to cirrhosis, time to lost to follow-up and time death using Laplace regression 
      msp = median survival percentile (50th); time to event calculated from enrolment 
      b Adjusted for: time since diagnosis, HCV genotype, chronic HBV infection, HIV infection, study site 
      c Adjusted for:  cirrhosis, time since diagnosis, HCV genotype, chronic HBV infection, HIV infection, study site 
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Table 3: Sensitivity analyses 
 
Groups Analyses Outcomes 
  Cirrhosis Loss to follow-up Mortality Treatment 
status 
Response to 
antivirals 
  HR (95% CI) HR (95% CI) HR (95% CI) OR (95% CI) OR (95% CI) 
 1 0.80 (0.60;1.06) 0.77 (0.62;0.95) 0.72 (0.35;1.47) 0.85 (0.66;1.09) 0.78 (0.55;1.10) 
Swiss employees 2 0.79 (0.58;1.09) 0.76 (0.60;0.97) 0.89 (0.40;2.00) 0.78 (0.59;1.05) 0.90 (0.61;1.32) 
 3 0.79 (0.61;1.04) 0.80 (0.66;0.98) 0.69 (0.36;1.32) 0.80 (0.63;1.01) 0.77 (0.55;1.07) 
 1 0.83 (0.63;1.09) 1.35 (1.11;1.64) 2.01 (1.07;3.79) 0.54 (0.42;0.69) 0.93 (0.66;1.31) 
PWID 2 0.81 (0.60;1.10) 1.28 (1.03;1.59) 2.17 (1.06;4.45) 0.50 (0.38;0.66) 0.94 (0.65;1.37) 
 3 0.85 (0.65;1.09) 1.40 (1.17;1.67) 1.92 (1.09;3.37) 0.46 (0.37;0.58) 0.89 (0.64;1.25) 
 1 1.89 (1.43;2.51) 0.83 (0.65;1.07) 2.40 (1.26;4.57) 0.93 (0.69;1.24) 0.70 (0.47;1.03) 
Male drinkers 2 1.84 (1.35;2.51) 0.79 (0.60;1.04) 2.24 (1.07;4.71) 0.90 (0.65;1.25) 0.75 (0.49;1.15) 
 3 1.90 (1.46;2.47) 0.80 (0.63;1.01) 2.35 (1.32;4.19) 0.84 (0.65;1.09) 0.67 (0.47;0.97) 
 1 2.45 (1.85;3.25) 0.85 (0.66;1.11) 2.22 (1.15;4.27) 0.69 (0.51;0.92) 0.48 (0.32;0.72) 
Retirees 2 2.41 (1.75;3.33) 0.81 (0.60;1.11) 2.76 (1.30;5.86) 0.75 (0.53;1.06) 0.51 (0.32;0.80) 
 3 2.44 (1.87;3.17) 0.83 (0.65;1.06) 2.21 (1.23;3.98) 0.73 (0.56;0.95) 0.43 (0.29;0.63) 
PWID: persons who inject drugs (former or current) 
HR: hazard ratio with 95% confidence interval (CI) 
OR: odds ratio with 95% confidence interval (CI) 
Analysis 1: missing HIV status was assumed to be negative 
Analysis 2: missing HIV status not replaced 
Analysis 3: missing HIV status and other explanatory variables replaced by multiple imputation 
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Box 1: Summary description of the groups 
1) Swiss employees (n = 1129, 25%) 
The median age at enrolment was 44 years (38-50 years). The majority were Swiss and employed with 
medium-high education. Most were no or light drinkers, but almost 40% were drug users. Gender was 
balanced. Median probability of belonging to the group: 0.92 (0.70-0.94). 
2) PWID (n = 1642, 37%) 
The median age at enrolment was 37 years (32-42 years). The majority were male and Swiss. They 
were drug users and 61% were current/former moderate-heavy drinkers. They had a medium-low 
education and 57% had social assistance or were unemployed. Median probability of belonging to the 
group: 0.85 (0.66-0.96). 
3) Male drinkers (n = 621, 14%) 
The median age at enrolment was 48 years (44-52 years). 84% were Swiss and almost all male. All 
were current/former moderate-heavy drinkers and almost 70% were drug users. Median probability 
of belonging to the group: 0.61 (0.57-0.64). 
4) Foreign employees (n = 497, 11%) 
The median age at enrolment was 41 years (35-49 years). All were foreigners and 41% were female. 
Nearly all members of this group were employed, the majority were no or light drinkers and a few 
were drug users. Median probability of belonging to the group: 0.76 (0.68-0.86). 
5) Retirees (n = 599, 13%) 
The median age at enrolment was 64 years (60-68 years). The majority were retired, none were drug 
users and most of them were no or light drinkers. The gender was balanced and 68% were Swiss. 
Median probability of belonging to the group: 0.99 (0.94-1.00). 
PWID: persons who inject drugs 
Drug use: ever injected drugs 
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Figure 1: Selection of persons for the analyses 
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Figure 2: Stepwise identification of socio-behavioural groups in latent class analysis 
The size of shaded boxes is proportional to the percentage of the 4,488 persons allocated to the groups. 
The five groups in the final model were assigned labels according to their most pertinent characteristics 
(see Box 1). 
 
PWID: persons who inject drugs
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Supplementary material 
Table 4: Sensitivity analysis to identify socio-behavioural groups with latent class analysis. 
 
 Swiss employees PWID Male drinkers Foreign employees Retirees 
 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 
No. of participants (%) 1,129 (25.2) 1,093 (24.3) 1,642 (36.6) 1,490 (33.2) 621 (13.8) 824 (18.4) 497 (11.1) 488 (10.9) 599 (13.3) 593 (13.2) 
Membership probability  
   (interquartile range) 
0.92 
(0.70-0.94) 
0.89 
(0.73-0.93) 
0.85 
(0.66-0.96) 
0.91 
(0.67-0.99) 
0.61 
(0.57-0.64) 
0.67 
(0.56-0.79) 
0.76 
(0.68-0.86) 
0.72 
(0.58-0.80) 
0.99 
(0.94-1.00) 
0.99 
(0.97-1.00) 
No. of women 618 (54.7) 515 (47.1) 526 (32.0) 524 (35.2) 6 (1.0) 116 (14.1) 203 (40.8) 195 (40.0) 305 (50.9) 308 (51.9) 
Median (interquartile range) age,       
years 44 (38-50) 45 (39-51) 37 (32-42) 35 (32-39) 48 (44-52) 47 (44-51) 41 (35-49) 41 (35-49) 64 (60-68) 64 (60-68) 
Swiss nationality 1,113 (98.6) 1,035 (94.7) 1,252 (76.2) 1,151 (77.2) 522 (84.1) 698 (84.7) 0 (0.0) 0 (0.0) 405 (67.6) 408 (68.8) 
Educationa           
   lower 77 (6.8) 61 (5.6) 603 (36.7) 504 (33.8) 14 (2.2) 141 (17.1) 138 (27.8) 134 (27.5) 134 (22.4) 126 (21.2) 
   medium 689 (61.0) 639 (58.5) 1,001 (61.0) 932 (62.5) 450 (72.5) 548 (66.5) 200 (40.2) 219 (44.99 334 (55.8) 336 (56.7) 
   higher 344 (30.5) 374 (34.2) 20 (1.2) 38 (2.5) 148 (23.8) 125 (15.2) 150 (30.2) 125 (25.6) 119 (19.9) 119 (20.1) 
Occupational status           
   worker / student 1,078 (95.5) 1,057 (96.7) 687 (41.8) 648 (43.5) 394 (63.4) 461 (56.0) 447 (89.9) 440 (90.2) 131 (21.9) 131 (22.1) 
   retired / social assistance 10 (0.9) 0 (0.0) 563 (34.3) 467 (31.3) 192 (30.9) 304 (36.9) 9 (1.8) 9 (1.8) 462 (77.1) 456 (76.9) 
   unemployed 35 (3.1) 31 (2.8) 385 (23.4) 369 (24.8) 33 (5.3) 55 (6.7) 37 (7.4) 35 (7.7) 3 (0.5) 3 (0.5) 
Alcohol consumptionb           
   no or light drinker 979 (86.7) 930 (85.1) 637 (38.8) 662 (44.4) 0 (0.0) 36 (4.4) 375 (75.4) 360 (73.8) 442 (73.8) 445 (75.0) 
   moderate-heavy drinker 39 (3.4) 52 (4.8) 331 (20.2) 282 (18.9) 211 (34.0) 241 (29.2) 26 (5.2) 35 (7.2) 56 (9.3) 53 (8.9) 
   former moderate-heavy drinker 111 (9.8) 111 (10.2) 674 (41.0) 546 (36.6) 410 (66.0) 547 (66.4) 96 (19.3) 93 (19.1) 101 (16.9) 95 (16.0) 
Drug use           
   no 688 (60.9) 712 (65.1) 16 (1.0) 19 (1.3) 190 (30.6) 157 (19.0) 457 (92.0) 467 (95.7) 594 (99.2) 587 (99.0) 
   current 
437 (38.7) 
249 (22.8) 
1,625 (99.0) 
1,355 (90.9) 
429 (69.1) 
413 (50.1) 
38 (7.6) 
0 (0.0) 
1 (0.2) 
1 (0.2) 
   former 121 (11.1) 105 (7.1) 248 (30.1) 19 (3.9) 0 (0.0) 
PWID: persons who inject drugs 
Model 1: model used for main analysis, with drug use divided into no or yes. 
Model 2: model used for sensitivity analysis, with drug use divided into no, current and former. 
a Education: defined according to the Swiss Conference of Cantonal Ministers of Education. 
b Alcohol consumption: no or light drinker (≤20 g alcohol/day), moderate-heavy drinker (>20 g alcohol/day) and former moderate-heavy drinker (used to drink >20 g 
alcohol/day before, but currently stopped). 
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